证券代码：000908 证券简称：*ST 景峰 公告编号：2025-030 湖南景峰医药股份有限公司 第八届董事会第三十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、湖南景峰医药股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日以电 子邮件、电话、即时通讯等方式发出了关于召开第八届董事会第三十八次会议的通 知。 2、公司第八届董事会第三十八次会议于 2025 年 4 月 27 日上午 9:30 在湖南省 常德经济技术开发区樟木桥街道双岗社区桃林路661号双创大厦18楼公司会议室以 现场及通讯相结合的方式召开。 3、会议应参加表决董事 8 人，实际参与表决董事 8 人（其中杨栋先生、叶高静 女士、谢树青先生、刘亭先生、徐一民先生以通讯方式参会）。 4、会议由代行董事长张莉女士主持，公司监事及高级管理人员列席了会议。 5、本次会议的通知、召集、召开、审议、表决程序均符合法律、行政法规、部 门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 1、《2024 年度董事会工作报告》； 本议案 ...

证券代码：000908 证券简称：*ST 景峰 公告编号：2025-032 湖南景峰医药股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 2024 年度利润分配预案为：不进行现金利润分配，亦不进行资本公积金转 增股本和其他形式的分配。公司不触及《深圳证券交易所股票上市规则》第 9.8.1 条第（九）项规定可能被实施其他风险警示的相关情形。 一、审议程序 湖南景峰医药股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开 第八届董事会第三十八次会议和第八届监事会第二十次会议审议通过《2024 年 度利润分配的议案》，该议案尚需提交公司 2024 年度股东大会审议。 二、公司 2024 年度利润分配预案 经大信会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司合并报表未分配利润为-1,045,952,305.52 元，母公司未分配利润为- 4,655,050,066.45 元。鉴于截至 2024 年 12 月 31 日公司合并报表和母公司未分 配利润仍为负 ...

证券代码：000908 证券简称：*ST 景峰 公告编号：2025-041 湖南景峰医药股份有限公司董事会 1、湖南景峰医药股份有限公司（以下简称"公司"）2024 年度财务报告 经大信会计师事务所（特殊普通合伙）（以下简称"大信"）审计，公司 2024 年 度经审计的期末净资产为正值，大信对公司出具《2024 年度审计报告》的审计 意见类型为带持续经营重大不确定性段落的无保留意见，《2024 年度内部控制 审计报告》的审计意见类型为标准无保留意见，同时出具了《关于湖南景峰医 药股份有限公司 2023 年度持续经营能力重大不确定性事项影响已消除的专项审 核报告》，并于2024年12月30日出具了《关于湖南景峰医药股份有限公司2023 年度内部控制审计报告非标事项已消除的专项审核报告》和《关于湖南景峰医 药股份有限公司 2023 年度审计报告保留意见涉及的部分事项影响已消除的专项 审核报告》。 根据《深圳证券交易所股票上市规则》（以下简称《股票上市规则》）的规 定，公司因触及《股票上市规则》第 9.3.1 条第一款第（二）项而被实施退市 风险警示的情形已消除，公司因触及《股票上市规则》第 9.8.1 条第一款第 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥100,110,799.34, a decrease of 0.46% compared to ¥100,575,702.29 in the same period last year[3] - The net profit attributable to shareholders was -¥11,899,583.20, representing a significant decline of 960.04% from -¥1,122,560.52 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥10,770,642.19, down 682.74% from ¥1,848,275.03 in the previous year[3] - Net profit for the current period was a loss of ¥11,179,695.86, compared to a profit of ¥371,857.08 in the previous period[16] - The company reported a comprehensive loss of ¥11,163,598.24, compared to a comprehensive income of ¥405,781.67 in the previous period[17] Cash Flow - The net cash flow from operating activities increased by 32.49% to ¥11,453,424.33, compared to ¥8,644,488.81 in the same period last year[3] - Operating cash inflow totaled ¥99,223,217.11, down 32.8% from ¥147,729,200.68 in the previous period[19] - Cash outflow from operating activities decreased to ¥87,769,792.78, down 37.0% from ¥139,084,711.87 in the previous period[20] - Cash flow from investment activities generated a net inflow of ¥1,894,591.35, compared to a net outflow of ¥415,900.00 in the previous period[20] - Cash outflow for investment activities decreased significantly to ¥47,400.00 from ¥587,700.00 in the previous period[20] - Cash flow from financing activities resulted in a net outflow of ¥23,274,399.69, worsening from a net outflow of ¥5,302,864.12 in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was a negative ¥15,959.86, compared to a negative ¥957,811.59 in the previous period[20] - The ending balance of cash and cash equivalents was ¥48,843,904.51, down from ¥14,923,877.12 in the previous period[20] - The company reported a significant increase in cash received from operating activities related to other business activities, totaling ¥22,234,418.93, up from ¥9,580,238.57[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥923,256,475.22, a decrease of 1.78% from ¥939,983,853.40 at the end of the previous year[3] - Total liabilities decreased slightly to ¥949,549,360.56 from ¥955,113,140.50, a reduction of 0.59%[13] - The company's equity attributable to shareholders decreased by 14.54% to ¥69,904,815.75 from ¥81,796,189.16 at the end of the previous year[3] - The company's equity attributable to shareholders decreased to ¥69,904,815.75 from ¥81,796,189.16, a decline of 14.56%[13] Operating Costs and Expenses - Total operating costs increased to ¥108,545,441.39, up 4.83% from ¥103,667,185.25 in the previous period[15] - Research and development expenses increased to ¥2,259,822.81, up 17.06% from ¥1,929,948.31 in the previous period[16] - Employee compensation payments decreased to ¥20,745,329.84, down 12.7% from ¥23,773,401.07 in the previous period[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 34,311[8] - Basic and diluted earnings per share were both -0.0135, compared to -0.0013 in the previous period[17] Other Income - The company reported a significant increase in other operating income by 162.92%, primarily due to arbitration compensation received[6] Return on Assets - The weighted average return on net assets was -15.69%, down 17.27% from 1.58% in the previous year[3]

Financial Performance - The company's operating revenue for 2024 was ¥416,031,777.19, a decrease of 36.67% compared to ¥656,893,837.84 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥152,304,308.31, representing a significant increase of 164.51% from a loss of ¥215,144,077.22 in 2023[17]. - The net cash flow from operating activities for 2024 was -¥5,550,958.03, a decline of 115.83% compared to ¥35,063,943.44 in 2023[17]. - Basic earnings per share for 2024 were ¥0.1731, a recovery from a loss of ¥0.2445 in 2023, marking an increase of 164.49%[17]. - Total assets at the end of 2024 were ¥939,983,853.40, down 11.35% from ¥1,060,346,384.15 at the end of 2023[17]. - The net assets attributable to shareholders increased to ¥81,796,189.16, a rise of 216.10% from a negative net asset of -¥49,494,383.93 in 2023[17]. - The revenue after deducting unrelated business income for 2024 was ¥411,270,408.86, slightly down from ¥415,018,671.17 in 2023[20]. - The company reported a net profit attributable to shareholders of -¥1,122,560.52 in Q1 2024, -¥31,929,272.43 in Q2, -¥15,766,895.78 in Q3, and a positive net profit of ¥201,123,037.04 in Q4[24]. - The pharmaceutical segment accounted for ¥391,273,715.21, representing 94.05% of total revenue, with a year-on-year decline of 37.86%[47]. - The gross margin for the pharmaceutical segment was 61.77%, down 9.79% from the previous year[48]. Challenges and Risks - The company has faced significant challenges, including a substantial decrease in revenue and cash flow, which may impact future operations[4]. - The audit report indicated a going concern uncertainty, highlighting the need for careful financial management moving forward[4]. - The company has experienced uncertainty regarding its ability to continue as a going concern, as indicated by negative net profits over the last three accounting years[20]. - The company triggered a default on its "16 Jingfeng 01" bonds, with an overdue principal of ¥29,463.92 million as of December 31, 2023, and a required additional provision for default penalties of ¥20,956,400[20]. - The restructuring process carries significant uncertainty, and if successful, it could optimize the company's capital structure and improve its operational sustainability[81]. Strategic Focus and Operations - The company is focusing on risk management and operational planning to navigate potential future challenges[4]. - The company plans to adopt new accounting policies effective January 1, 2024, regarding data resources, which will not have a significant impact on its financial statements[20]. - The company aims to maintain its core competitiveness by providing high-quality products and services while continuously improving its operational efficiency[36]. - The company is actively expanding its market presence in private hospitals and county-level medical markets, expecting stable sales growth[43]. - The company is focusing on enhancing its marketing strategies and deepening collaborations with grassroots medical institutions to increase market share[43]. Research and Development - The company has a robust R&D pipeline, with products in various therapeutic areas, including cardiovascular, oncology, and pain management[43]. - The R&D model emphasizes self-research and collaborative development, with a focus on innovative drugs and timely market entry[35]. - The company aims to diversify its product pipeline, focusing on a mix of innovative drugs, generics, and traditional Chinese medicine[42]. - The company has successfully won exclusive bids for sodium hyaluronate injection in multiple provincial procurement alliances, demonstrating strong market influence in orthopedics[39]. Governance and Management - The company has maintained an independent governance structure, ensuring no interference from the controlling shareholder in decision-making processes[89]. - The company has established a value management system and is focused on enhancing investor communication and governance practices[87]. - The management team effectively oversees daily operations without exceeding their authority, ensuring the protection of the company's and shareholders' interests[91]. - The board of directors operates in compliance with legal requirements, with a clear structure and effective supervision of management actions[90]. - The company is undergoing significant management changes with multiple resignations and new appointments in 2024[97]. Environmental Compliance - The company strictly adheres to environmental protection laws and regulations, ensuring compliance with various national and local standards[129]. - Guizhou Jingfeng received a wastewater discharge permit on May 25, 2023, valid until May 24, 2028[130]. - Guizhou Jingfeng's wastewater discharge includes COD at 18 mg/L, below the limit of 60 mg/L, with a total discharge of 1.70371 tons[132]. - Guizhou Jingfeng's comprehensive wastewater treatment station has a processing capacity of 1,000 tons per day, operational since 2011, achieving compliant discharge[133]. Legal Matters - The company is involved in multiple significant lawsuits, including a dispute with Wuyi Huijun Investment Partnership amounting to 51.85 million yuan, currently in the execution phase[153]. - The company has faced a first-instance judgment rejecting all claims in a lawsuit against Anquan and others, with a disputed amount of 30.43 million yuan[153]. - The company has several other lawsuits in various stages, with a total amount of 18.93 million yuan involved, none of which are expected to have a significant impact on the company[154]. Shareholder and Equity Structure - The largest shareholder, Ye Xiangwu, holds 13.86% of the total shares, amounting to 121,902,286 shares, with 119,130,000 shares pledged[186]. - The second largest shareholder, China Great Wall Asset Management Co., Ltd., holds 12.92% of the total shares, totaling 113,680,665 shares[186]. - The company has not experienced any changes in its controlling shareholder during the reporting period[188]. - The total number of shareholders at the end of the reporting period is not specified, but significant changes in shareholding structure were not reported[184]. Debt and Financial Obligations - The company has issued a bond of 800 million yuan, with 505.36 million yuan repaid by the end of 2023, and 294.64 million yuan overdue, with the latest extension agreed until June 30, 2024[148]. - The company has committed to pay CNY 295 million in principal and interest for the bonds by July 1, 2024[156]. - The total approved guarantee amount for subsidiaries at the end of the reporting period is 26,800 million, with an actual guarantee balance of 26,151 million[173].

证券代码：000908 证券简称：*ST景峰 公告编号：2025-029 湖南景峰医药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 1、召开时间： 现场会议召开时间：2025 年 4 月 24 日（星期四）15:00； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 4 月 24 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过互联网投票系统投 票的时间为 2025 年 4 月 24 日 9:15-15:00。 2、召开地点：湖南省常德经济技术开发区樟木桥街道双岗社区桃林路 661 号双创大厦 18 楼湖南景峰医药股份有限公司会议室 3、召开方式：现场投票和网络投票相结合的方式 特别提示： 1、本次股东大会没有出现否决议案、增加或减少议案的情形。 2、本次股东大会没有涉及变更以往股东大会决议。 一、会议召开和出席情况 4、召集人：公司董事会 5、主持人：代理董事长张莉女士 6、会议的召开符合《公司法》等有关法律、行政法规、部门规章和《公司 章程》的规 ...

证券代码：000908 证券简称：*ST景峰 公告编号：2025-028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 湖南景峰医药股份有限公司 1、湖南景峰医药股份有限公司（以下简称"公司"）于2024年4月30日披露 了《关于公司股票交易被实施退市风险警示叠加其他风险警示暨股票停复牌的公 告》（公告编号：2024-027），公司股票于2024年5月6日开市起被实施退市风险 警示。若公司出现《深圳证券交易所股票上市规则（2024年修订）》（以下简称 《股票上市规则》）第9.3.12条规定的情形，公司股票存在被终止上市的风险。 关于公司股票可能被终止上市的第七次风险提示公告 公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值，且最 近一年审计报告显示公司持续经营能力存在不确定性，属于根据《深圳证券交易 所股票上市规则（2023年8月修订）》第9.8.1条第一款第（七）项之公司股票交 易被实施其他风险警示的情形，公司股票被叠加实施其他风险警示。 上述具体内容详见公司于2024年4月30日在巨潮资讯网披露的《关于公司股 票交易被实施退市风险 ...

关于 湖南景峰医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年四月 广东崇立律师事务所 法律意见书 深圳市龙岗区坂田街道雅宝路 1 号星河 World F 栋 18 层 F1806 号 邮政编码：518100 Suite F1806, 18F, Xinghe World Tower F, No.1Yabao Road, Bantian Street, Longgang District, Shenzhen 电话/Tel：0755-8958 5892 传真/Fax：0755-8958 6631 www.chonglilaw.com 广东崇立律师事务所 关于湖南景峰医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 （2025）崇立法意第 11 号 致：湖南景峰医药股份有限公司 广东崇立律师事务所（以下简称"本所"）接受湖南景峰医药股份有限公 司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第一次临时股 东大会（以下简称"本次股东大会"）进行法律见证，并依据《中华人民共和 国公司法（2023 修订）》（以下简称《公司法》）、《中华人民共和国证券法 （2019 ...

湖南景峰医药股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、公司已进入预重整程序，公司能否进入重整程序尚存在不确定性。鉴 于上市公司重整申请审查流程较为复杂，本次重整申请能否被受理存在重大不 确定性。 2、石药控股集团有限公司（以下简称"石药集团"）虽已缴纳尽调保证 金并提交预重整投资方案中选为预重整投资人，但重整事项仍面临多重不确定 性，包括但不限于重整方案的最终确定、权益调整安排、重整投资款项支付、 股价及重整投资成本、重整投资人内部审议程序、司法审查程序、债权人会议 审议结果及股东大会审议结果等。因此，石药集团最终能否参与重整并执行完 毕重整计划尚存在重大不确定性。 3、自 2024 年 5 月 6 日起，公司股票交易被实施退市风险警示和其他风险 警示；截至本公告披露日，公司 2023 年度内部控制审计报告否定意见涉及事项 的影响已消除；2023 年度财务会计报告审计报告部分保留意见涉及事项的影响 已消除，保留意见涉及的"持续经营能力重大不确定性"事项的影响暂未消除。 经公司财务部门初步核算，并与 ...

债券代码：112468 债券简称：16景峰01 债券受托管理人 摩根士丹利证券（中国）有限公司 关于 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 2025 年 4 月 1 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 重要声明 受托管理事务临时报告 （一）本次交易的基本情况 大连市金州区人民法院于2023年11月24日依法裁定受理武义慧君投资合伙企业（有限合 伙）对大连德泽药业有限公司（以下简称"大连德泽"）的清算申请，并于2023年12月6日指 定辽宁德中律师事务所、致同会计师事务所（特殊普通合伙）辽宁分所联合体担任大连德泽 药业有限公司清算组。现大连市金州区人民法院已裁定确认大连德泽清算组的清算方案，大 连德泽资产已上网进入清算拍卖，主要标的资产包括大连德泽持有的大连华立金港药业有限 公司100%的股权、大连德泽名下的无形资产、大连德泽厂区内固定资产、生产用原材料等 整体打包，起拍价为312,857,118.65元。公司子公司常德景诚医药科技有限公司（以下简称 "常德景诚"）拟与石药控股集团有限公司（以下简称" ...